An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

Trial Profile

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Idalopirdine (Primary) ; Memantine
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Acronyms STAR Extension
  • Sponsors Lundbeck A/S
  • Most Recent Events

    • 25 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 20 Jun 2017 The trial has been completed in Denmark.
    • 31 Mar 2017 Planned End Date changed from 1 Jan 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top